Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.
Advertisement

Related Content

Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications
Rebif Ready For Antegren Following MS Market Share Gains, Serono Says
Biogen Idec Doubling Multiple Sclerosis Sales Force For Antegren Launch
Elan Prialt NDA Amendment Puts Drug On Schedule For Early 2005 Launch
Elan Assembles Antegren Team; Hires Four Execs Ahead Of FDA Approval
Monoclonal Antibodies for Inflammatory Bowel Disease Take Center Stage At Digestive Disease Week
Elan/Biogen Idec Antegren Will Set Premium Price In Multiple Sclerosis
Elan/Biogen Idec Antegren Multiple Sclerosis Filing Slated For Mid-Year
Elan/Biogen Idec Antegren Multiple Sclerosis Filing Slated For Mid-Year

Topics

Advertisement
UsernamePublicRestriction

Register

PS059509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel